Announcements Trials
Browse Landscape

Phase

Phase 3 1Phase 1/2 1

Status

Recruiting 2

Sponsor Class

OTHER 1INDUSTRY 1

Study Type

Interventional 2

Sponsor

Cancer Type

Genitourinary 2

Conditions

Prostatic Neoplasms 58Prostatic Neoplasms, Castration-Resistant 5Neoplasm Metastasis 4Metastatic Castration-resistant Prostate Cancer 4Prostatic Diseases 3Neoplasms 3Breast Neoplasms 3Adenocarcinoma 3Triple Negative Breast Neoplasms 2Salivary Gland Neoplasms 2Male Urogenital Diseases 2Genital Diseases, Male 2Bulbo-Spinal Atrophy, X-Linked 2Biochemically Recurrent Prostate Cancer 2Urogenital Neoplasms 1Urogenital Diseases 1Thrombocytosis 1Refractory or Relapsed Solid Tumors 1Prostate Cancer Non-Metastatic 1Prostate Cancer Metastatic 1Prostate Adenocarcinoma 1Primary Myelofibrosis 1Precursor Cell Lymphoblastic Leukemia-Lymphoma 1Pancreatic Neoplasms 1Neoplasms by Site 1Myeloproliferative Disorders 1Myelodysplastic-Myeloproliferative Diseases 1Myelodysplastic Syndromes 1Multiple Myeloma 1Metastatic Hormone-sensitive Prostate Cancer 1

Interventions

padeliporfin 4darolutamide 2apalutamide 2palladium-bacteriopheophorbide 1onapristone 1niraparib 1ixabepilone 1gedatolisib 1gallium 68 PSMA-11 1enzalutamide 1abiraterone 1Therapeutics 1Standard of Care 1Radiotherapy 1Prednisone 1Pluvicto 1Imatinib Mesylate 1EPI-506 1Docetaxel 1BAY 86-7548 1Androgen Antagonists 1Abiraterone Acetate 12-(3-(1-carboxy-5-((6-fluoropyridine-3-carbonyl)amino)pentyl)ureido)pentanedioic acid 1(225)Ac-PSMA-617 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Interventional × Genital Diseases, Male × darolutamide × Clear all
NCT06190899 2026-04-13

Gedatolisib in Combination With Darolutamide in Metastatic Castration-Resistant Prostate Cancer

Celcuity Inc

Phase 1/2 Recruiting
54 enrolled
Genitourinary

Genital Diseases, Male, Prostatic Diseases, Prostatic Neoplasms, Male Urogenital Diseases, Prostatic Neoplasms, Castration-Resistant

NCT06496581 2024-12-20

Standard of Care +/- 177Lu-PSMA-617 In de Novo mHSPC Patients With Poor PSA Response (PEACE6-Poor Responders)

UNICANCER

Phase 3 Recruiting
500 enrolled
Genitourinary

Genital Diseases, Male, Prostatic Diseases

Data powered by HemOnc (CC BY 4.0) Colophon âš¡